Home Biosimilar Antibodies Others Others Vilobelimab (Anti-Complement C5)
For research use only. Not for use in humans.

Vilobelimab (Anti-Complement C5)

Synonyms: CaCP-29, IFX-1

Vilobelimab (Anti-Complement C5) is a monoclonal antibody targeting C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. It may be used in studies related to sepsis, COVID-19, etc. MW :145.9 KD.

Vilobelimab (Anti-Complement C5)

Quality Control

Batch: A310101 Purity: 99% Protein concentration: 5.5mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Vilobelimab (Anti-Complement C5) is a monoclonal antibody targeting C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. It may be used in studies related to sepsis, COVID-19, etc. MW :145.9 KD.
References

Product Details

CAS No. 2250440-41-4
Isotype Human IgG4SP
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07520318 NOT_YET_RECRUITING Drug: bispecific anti-VEGF and anti-complement Adults With Neovascular Age-related Macular Degeneration Shenzhen Oculgen Biomedical Technology Co., Ltd. 2026-04-17 PHASE2; PHASE3
NCT06703073 RECRUITING Drug: Cohort A: vilobelimab|Drug: Cohort A: placebo|Drug: Co Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome); Acute Respiratory Distress Syndrome PPD Development, LP 2025-06-10 PHASE2
NCT06701682 RECRUITING Drug: Cohort A: vilobelimab|Drug: Cohort A: placebo Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome); Acute Respiratory Distress Syndrome PPD Development, LP 2025-06-21 PHASE2
NCT05964413 TERMINATED Drug: vilobelimab|Drug: Placebo Pyoderma Gangrenosum InflaRx GmbH 2023-11-01 PHASE3
NCT04812535 TERMINATED Drug: Vilobelimab|Drug: Vilobelimab + pembrolizumab combinat SCC - Squamous Cell Carcinoma of Skin InflaRx GmbH 2021-03-31 PHASE2
NCT03971643 COMPLETED Drug: vilobelimab Pyoderma Gangrenosum InflaRx GmbH 2019-05-16 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-04-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.